Effect of Lipikar Urea 30% Before Actinic Keratoses Treatment
This study is conducted in one center in Germany, in adult subjects having actinic keratoses (grade I or II) lesions on the scalp and meeting specific inclusion/exclusion criteria. The purpose of the study is to evaluate a holistic management (efficacy, tolerability and lesion cosmetic outcomes) of Tolak® treatment.
- EligibilityCriteria: Inclusion Criteria:  diagnosis of at least 4 non-hypertrophic, non-hyperkeratotic actinic keratosis of the the scalp planned treatment of actinic keratoses of the scalp with Tolak® Olsen grade I or II  Exclusion Criteria:  known or documented intolerance to any of the ingredients of Tolak® or Lipikar Urea 30% treatment of actinic keratoses in the treatment area within the past 3 months (e.g. photodynamic therapy, topical 5-FU, diclofenac, imiquimod, cryotherapy etc.) suspected invasive squamous cell cancer in the treatment area chronic wounds, erosions, pre-existing inflamed or infected skin with disruption of the epidermal barrier in the treatment area current or within the last 8 weeks given systemic cancer medication or systemic treatment with 5-Fluorouracil - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult